April 1, 2021 5:36pm

April Fool’s Day: does Biostage (BSTG -$0.00) think they’re fooling public and minority shareholders by not filing their Q4 and FY20 financials on time?

Pre-open indication results: 1 HIT and 0 Miss

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence

Numbers based facts speak better then opinion as I see answers in numbers that equate to facts!

The Dow closed UP +171.66 points (+0.52%); the S&P closed UP +46.98 points (+1.18%) while the Nasdaq closed UP +233.24 points (+1.76%)

 

Henry’omics:

Indexes moved higher as the cell and gene therapy sector also hit new highs for the week to start the month on its first session.

U.S. stock markets will close on Good Friday for the holiday.

For the shortened week, the S&P 500 rose 1.1%, the Dow gained 0.25% and the Nasdaq added 2.6%.

 

Data Docket: U.S. manufacturing activity jumped to a reading of 64.7 last month from 60.8 in February, according to the Institute for Supply Management. That was the highest level since December 1983.

  • The key March jobs report will be released on Friday, although the stock market will be closed for the Good Friday holiday. Economists expect 630,000 jobs were added in March, and the unemployment rate fell to 6% from 6.2%.

 

RegMed Investors’ (RMi) pre-open: “Q2 begins as holiday closes in” … https://www.regmedinvestors.com/articles/11843

 

Pre-open indication results:  1 HIT <Maintain SELL: Biostage (BSTG -$0.00 with 26 shares) and 0 MISS

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Thursday opened positive at 27/6, 1 flat and 1 acquired, stayed positive at the mid-day to 24/8, 2 flats and 1 acquired, closing positive at 19/13, 2 flat and 1 acquired;
  • Wednesday opened positive at 25/8, 1 flat and 1 acquired, stayed positive at the mid-day to 26/7, 2 flats and 1 acquired, closing positive at 29/3, 2 flat and 1 acquired;
  • Tuesday opened negative at 4/29, 1 flat and 1 acquired, strayed positive at the mid-day to 24/10 and 1 acquired, closing positive at 23/9, 2 flat and 1 acquired;
  • Monday opened negative at 8/24, 12 flat and 1 acquired, stayed negative at the mid-day to 6/26, 2 flat and 1 acquired, closing negative at 6/27, 1 flat and 1 acquired;

 

There are clear winners and losers

Jumping with share pricing momentum: yesterday’s dogs get to bark again

  • Intellia Therapeutics (NTLA), Global Blood Therapeutics (GBT), Editas Medicine (EDIT), Sage Therapeutics (SAGE), Fate Therapeutics (FATE), to name 5 of the 19 inclining of the 35 covered

Hammered in today’s market:

  • Vericel (VCEL), AxoGen (AXGN), Ultragenyx (RARE), Sangamo Therapeutics (SGMO), CRISPR Therapeutics (CRSP) to name 5 of the 13 declining of the 35 covered

 

Key metrics:

  • Sector volume had LOW with 5 of the 19-upside having higher than the 3-month average volume with the volume of 3 of 13-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 19-upside were +0.20% (IONS) to +7.22% (ATHX) while the 13-downside ranges from -0.24% (NTLA) to -4.23% (VCEL);

 

Thursday’s (10 of 19) incline

  • Sage Therapeutics (SAGE +$2.03 after Wednesday’s +$1.57, Tuesday’s +$1.68 and Monday’s -$2.14);
  • Global Blood therapeutics (GBT +$1.87);
  • Editas Medicine (EDIT +$0.83 after Wednesday’s +$1.50);
  • BioLife Solutions (BLFS +$0.69);
  • MiMedx (MDXG +$0.62);
  • Alnylam Pharmaceuticals (ALNY +$0.62 after Wednesday’s +$6.06, Tuesday’s +$1.33 and Monday’s -$2.45);
  • uniQure NV (QURE +$0.42);
  • Regenxbio (RGNX +$0.25);
  • Adverum Biotechnologies (ADVM +$0.22);
  • Homology Medicine (FIXX +$0.21);

Thursday’s (13 of 13) decliners:

  • CRISPR Therapeutics (CRSP -$2.44 after Wednesday’s +$6.65, Tuesday’s +$4.48 and Monday’s -$0.52);
  • Vericel (VCEL -$2.35 after Wednesday’s +$2.91, Tuesday’s +$1.59 and Monday’s -$0.59);
  • Ultragenyx (RARE -$0.66 after Wednesday’s +$1.80, Tuesday’s +$3.12 and Monday’s -$1.74);
  • Fate Therapeutics (FATE -$0.54 after Wednesday’s +$8.36, Tuesday’s +$1.32 and Monday’s +$0.61),
  • Cellectis SA (CLLS -$0.47 after Wednesday’s +$1.40 and Tuesday’s -$0.29);
  • AxoGen (AXGN -$0.40);
  • Sangamo Therapeutics (SGMO -$0.25);
  • Intellia Therapeutics (NTLA -$0.19 after Wednesday’s +$8.01, Tuesday’s +$6.93 and Monday’s +$0.58);
  • bluebird bio (BLUE -$0.11 after Wednesday’s +$1.53, Tuesday’s -$2.32 and Monday’s +$0.96);
  • Solid Biosciences (SLDB -$0.09);
  • Bellicum pharmaceuticals (BLCM -$0.07);
  • Chinook Therapeutics (KDNY -$0.04 after Wednesday’s -$1.20, Tuesday’s +$1.09 and Monday’s -$1.08);
  • Caladrius Bioscience (CLBS -$0.03);

Closing: 2 – ReNeuron (RENE.L), Biostage (BSTG) and 1 - Stemline Therapeutics (STML – acquired)

 

Sentiment and COVID-19 infections: improving with ...

  • Total vaccines administered – 154 M

Infection cases <Million>: never to forget …

  • Thursday 30.27 M cases,
  • Thursday’s death rate totaled 549,098 <Johns Hopkins University>

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed UP +0.64% and XBI closed up +1.02%
  • Wednesday, the IBB closed UP +2.65% and XBI closed up +4.26%
  • Tuesday, the IBB closed down -0.39% and XBI closed up +0.58%
  • Monday, the IBB closed down -1.27% and XBI closed down -2.78%

 

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -2.07 points or -10.67% at 17.33
  • Wednesday was down – 0.21points or -1.07% at 19.40
  • Tuesday was down -1.13 points or -5.45% at 19.61
  • Monday was up +1.88 points or +9.97% at 20.74

 

Upside volume: low

  • Thursday: 5 out of the 19-upside had higher than the 3-month average volume;
  • Wednesday: 6 out of the 29-upside had higher than the 3-month average volume;
  • Tuesday: 6 out of the 24-upside had higher than the 3-month average volume;
  • Monday: 4 out of the 6-upside had higher than the 3-month average volume;

 

Downside volume: low

  • Thursday: 3 out of the 13-downside had higher than the 3-month average volume;
  • Wednesday: 1 out of the 3-downside had higher than the 3-month average volume;
  • Tuesday: 0 out of the 9-downside had higher than the 3-month average volume;
  • Monday: 0 out of the 27-downside had higher than the 3-month average volume;

 

Percentage (%) movement/range statistics: % and pricing drop

  • Thursday’s percentage (%) of the 19-upside were +0.20% (IONS) to +7.22% (ATHX) while the 13-downside ranges from -0.24% (NTLA) to -4.23% (VCEL);
  • Wednesday’s percentage (%) of the 29-upside were +0.11% (BLFS) to +11.28% (FATE) while the 3-downside ranges from -1.88% (VYGR) to -7.17% (KDNY);
  • Tuesday’s percentage (%) of the 24-upside were +0.21% (ADVM) to +10.61% (NTLA) while the 9-downside ranges from -0.12% (RGNX) to -8.33% (BSTG);
  • Monday’s percentage (%) of the 6-upside were +0.85% (FATE) to +4.68% (IONS) while the 27-downside ranges from -0.21% (CLBS) to -9.15% (PGEN);

 

April, the beginning of Q2/21:

Thursday closed positive with 19 advancers, 13 decliners, 2 flat and 1 acquired

 

The BOTTOM LINE: As the market closed on the first day of the month and Q2 were on the winning side of trading today …

The question will be, are sector investors ready for the Monday open and potential DRFT of share pricing?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.